EFFECT OF TOCILIZUMAB ON OUTCOMES OF COVID PATIENTS WITH OBESITY

ABSTRACT

Included patients had a BMI>30, required intensive care unit (ICU) level care, and positive pressure ventilation (high-flow nasal canula, continuous or bilevel positive airway pressure, mechanical ventilation). B Introduction/Hypothesis: b Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of patients worldwide since its emergence in 2019. B Conclusion: b Despite an elevated BMI, the associated mortality rate of patients who received tocilizumab in this study was similar to the mortality rate of the tocilizumab group in the RECOVERY trial. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)